Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493131 | 0.91 | TP53 (0.57) | TP53MAPTLMNASMOPOLB | |
| SCHEMBL6503326 | 0.90 | SMO (0.54) | TP53LMNASMOKDM4E | |
| SCHEMBL6794470 | 0.84 | TP53 (0.54) | TP53MAPTLMNASMOPOLB | |
| SCHEMBL6488763 | 0.84 | MTTP (0.51) | TP53MAPTLMNASMOPOLB | |
| SCHEMBL6492083 | 0.82 | SMO (0.54) | TP53LMNASMO | |
| SCHEMBL6500792 | 0.81 | NPC1 (0.52) | TP53MAPTLMNASMOKDM4E | |
| SCHEMBL6497710 | 0.79 | POLB (0.49) | TP53MAPTLMNAGRM5POLB | |
| SCHEMBL6498250 | 0.79 | POLB (0.49) | TP53MAPTLMNAGRM5POLB | |
| SCHEMBL7162887 | 0.78 | MAPT (0.48) | TP53MAPTLMNAGRM5POLB | |
| SCHEMBL6794654 | 0.77 | GAA (0.57) | TP53MAPTLMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TP53 3031/4885MAPT 4202/4885LMNA 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.